KalVista Pharmaceuticals (KALV)

[Jk384]

Yea who knows what the patents are worth. If a buyer thinks the would get FDA approval probably several dollars per share? In addition to the $1.63 in net cash. Below is from their website not just for knee...

Pipeline (Other joints):  We have focused our product development efforts on developing Hydros-TA for the treatment of osteoarthritis (OA) pain in the knee. As this program progresses along the path to regulatory approval in the United States, we may explore the potential use of Hydros-TA in treating pain in other joints affected by OA. Joints affected by OA include the finger, hip, shoulder, ankle and temporomandibular joints. The initial target for the next product development effort for OA may likely be the hip joint.